Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...
Annual Revenue Grew 27% Year-Over-Year to a Record $202.5 Million13th Consecutive Quarter of Positive Adjusted EBITDAAnnual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results